Naratriptan hydrochloride - Generic Drug Details

What are the generic sources for naratriptan hydrochloride and what is the scope of patent protection?

Naratriptan hydrochloride is the generic ingredient in two branded drugs marketed by Glaxosmithkline Llc, Ani Pharms, Apotex Corp, Aurobindo Pharma Usa, Chartwell Rx, Heritage, Hikma, Orbion Pharms, Padagis Us, and Sun Pharm Inds Ltd, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for naratriptan hydrochloride. Three suppliers are listed for this compound.

Summary for naratriptan hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	10
NDAs:	10
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	10
What excipients (inactive ingredients) are in naratriptan hydrochloride?	naratriptan hydrochloride excipients list
DailyMed Link:	naratriptan hydrochloride at DailyMed

Recent Clinical Trials for naratriptan hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AgoneX Biopharmaceuticals, Inc.	Phase 2
BioHealthonomics Inc.	Phase 2
Ache Laboratorios Farmaceuticos S.A.	Phase 3

See all naratriptan hydrochloride clinical trials

Pharmacology for naratriptan hydrochloride

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for naratriptan hydrochloride

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for naratriptan hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex Corp	NARATRIPTAN	naratriptan hydrochloride	TABLET;ORAL	091373-001	Apr 22, 2011		DISCN	No	No
Padagis Us	NARATRIPTAN	naratriptan hydrochloride	TABLET;ORAL	091326-001	Jul 8, 2010	AB	RX	No	No
Hikma	NARATRIPTAN	naratriptan hydrochloride	TABLET;ORAL	090381-002	Jul 7, 2010	AB	RX	No	No
Sun Pharm Inds Ltd	NARATRIPTAN	naratriptan hydrochloride	TABLET;ORAL	091552-001	Feb 14, 2011		DISCN	No	No

Expired US Patents for naratriptan hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-002	Feb 10, 1998	4,997,841
Glaxosmithkline Llc	AMERGE	naratriptan hydrochloride	TABLET;ORAL	020763-001	Feb 10, 1998	4,997,841

Market Dynamics and Financial Trajectory for Naratriptan Hydrochloride

Last updated: February 20, 2026

What Is Naratriptan Hydrochloride?

Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist used primarily to treat acute migraine attacks. Approved in 1998 by the U.S. Food and Drug Administration (FDA), it belongs to the triptan class of medications. Prescriptions often occur for patients with moderate to severe migraines, especially those unresponsive to non-specific analgesics.

Market Overview

The global triptan market, with naratriptan as a key product, was valued at approximately $1.2 billion in 2022. Market growth is driven by increasing migraine prevalence, expanding awareness, and development of novel formulations.

Key Market Players

• GlaxoSmithKline (GSK): Former manufacturer of Naratriptan
• Menarini Group: Currently markets naratriptan in various regions
• Mylan (now part of Viatris): Was involved in generic manufacturing
• Other generic manufacturers: Limited regional players

Patent Status and Market Exclusivity

The original patent for naratriptan expired in the early 2000s. Generic entries followed, reducing prices and expanding access. GSK's branded product, Amerge, faced generic competition, with several manufacturers providing generic versions.

Market Dynamics

Regulatory Environment

• Regional approval differences impact sales volume. For example, naratriptan is approved in the U.S., EU, Japan, and emerging markets.
• Prescription regulations influence distribution; stricter controls reduce off-label use.

Competitive Landscape

• Several triptans (rizatriptan, sumatriptan, zolmitriptan) erect competitive barriers.
• Recent focus on oral formulations and fast-absorbing forms reduces naratriptan's market share.

Prescribing Trends

• Preference shifts toward triptans with faster onset of action or fewer side effects.
• Growing use of combination therapies with NSAIDs limits the share of monotherapy drugs like naratriptan.

Market Penetration and Patient Preference

• Naratriptan's lower side effect profile favors its use in vulnerable populations, such as adolescents.
• The availability of generics has increased accessibility but impacted profit margins for producers.

Financial Trajectory

Revenue Trends

Year	Estimated Global Revenue	Notes
2020	$0.9 billion	Market stabilizing post-generic entry
2021	$1.0 billion	Increment due to new patient groups
2022	$1.2 billion	Increased adoption in emerging markets

Pricing Dynamics

• Branded naratriptan (Amerge) in 2020: Average retail price per tablet approximately $10.
• Generic versions: Price drops of 50-70%, average <$4 per tablet.
• Price elasticity has increased, leading to narrower profit margins.

R&D and Pipeline

No recent major R&D investments confirmed for naratriptan-specific innovations. Most development efforts focus on alternative delivery systems and combination drugs.

Outlook and Future Financial Trends

• Market is expected to grow modestly at 3-5% annually through 2025.
• Growth driven by expanding migraine diagnosis, especially in developing regions.
• Patent expiries and increased generic competition will exert price pressure.

Challenges and Opportunities

Challenges

• High competition from other triptans and emerging migraine therapies.
• Shift toward CGRP inhibitors and gepants limits traditional triptan use.
• Pricing pressures and reimbursement restrictions.

Opportunities

• Development of novel formulations (e.g., nasal spray, fast-dissolving tablets) could reinvigorate market share.
• Expanding into emerging markets with lower-cost generics.
• Potential repositioning for chronic migraine management.

Regulatory and Policy Impacts

• Updated guidelines recommend personalized migraine treatment, affecting prescribing habits.
• Patent challenges and biosimilar regulations influence market entry strategies.
• Pricing negotiations and formulary restrictions impact product availability.

Conclusion

Naratriptan hydrochloride's market is characterized by a mature phase with established competition and pricing challenges. While overall revenue remains stable, growth prospects hinge on formulation innovations and market penetration in underpenetrated regions. The advent of new drug classes, notably CGRP inhibitors, continues to reshape the landscape, pressuring traditional triptans.

Key Takeaways

• Market value was approximately $1.2 billion in 2022, with modest growth.
• Generic competition has significantly reduced prices and profit margins.
• Market share is declining somewhat due to newer pharmacotherapies.
• Future growth depends on formulation innovation and expanding access in emerging markets.
• Regulatory changes and evolving treatment guidelines shape the competitive landscape.

FAQs

1. Will naratriptan regain market share from newer migraine drugs?
Limited growth prospects depend on formulation improvements and regional access; however, CGRP inhibitors are expected to continue capturing larger market segments.

2. How does patent expiration affect naratriptan’s profitability?
Patent expiry led to significant generic competition, sharply reducing prices and margins for branded versions.

3. Are there ongoing R&D efforts for naratriptan?
No confirmed large-scale R&D projects; focus lies on alternative delivery methods and combination therapies.

4. How do regional regulations influence naratriptan sales?
Approval variances impact prescription volumes; markets with supportive policies see higher adoption.

5. What is the outlook for naratriptan in emerging markets?
Growth potential is high due to lower costs, increased healthcare infrastructure, and unmet demand for migraine treatment.

---

References

1. GSK. (2023). Amerge (naratriptan hydrochloride) Prescribing Information. Retrieved from [GSK official website].
2. MarketWatch. (2022). Migraine Drugs Market Analysis.
3. U.S. Food and Drug Administration. (1998). FDA Approval for Naratriptan.
4. GlobalData. (2022). Triptans Market Report.
5. IQVIA. (2023). Pharmaceutical Sales Data.